Roivant Sciences Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ROIV Nasdaq 8731 http://roivant.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Roivant Sciences Ltd

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million - Apr 2nd, 2024 11:00 am
Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck - Mar 27th, 2024 5:55 pm
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 - Mar 26th, 2024 10:22 pm
Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations - Feb 14th, 2024 12:13 pm
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update - Feb 13th, 2024 12:00 pm
Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares - Feb 10th, 2024 7:55 am
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 - Jan 30th, 2024 9:05 pm
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease - Dec 20th, 2023 9:30 pm
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease - Dec 14th, 2023 2:00 pm
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential - Nov 28th, 2023 12:00 pm
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus - Nov 27th, 2023 1:00 pm
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update - Nov 13th, 2023 12:00 pm
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors - Nov 10th, 2023 1:00 pm
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 - Oct 30th, 2023 9:30 pm
Roche acquires Telavant, rights to bowel disease drug - Oct 23rd, 2023 1:52 pm
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant - Oct 23rd, 2023 5:00 am
Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer - Oct 13th, 2023 12:00 pm
Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV) - Oct 5th, 2023 9:01 am
Insider Sell: President & COO Eric Venker Sells 500,000 Shares of Roivant Sciences Ltd (ROIV) - Sep 30th, 2023 9:00 am
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results - Sep 26th, 2023 10:00 am